Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

Xuegang Yang,1,2 Heping Deng,3 Yanyuan Sun,1 Yi Zhang,3 Yujie Lu,3 Guohui Xu,1,* Xiaoqi Huang2,* 1Department of Interventional Therapy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu, People’s Republic of China; 2Huaxi MR Research Center (HMRRC), Functional and...

Full description

Bibliographic Details
Main Authors: Yang X, Deng H, Sun Y, Zhang Y, Lu Y, Xu G, Huang X
Format: Article
Language:English
Published: Dove Medical Press 2023-02-01
Series:Journal of Hepatocellular Carcinoma
Subjects:
advanced hepatocellular carcinoma
regorafenib
immune checkpoint inhibitors
transarterial chemoembolization
second-line treatment.
Online Access:https://www.dovepress.com/efficacy-and-safety-of-regorafenib-plus-immune-checkpoint-inhibitors-w-peer-reviewed-fulltext-article-JHC

Internet

https://www.dovepress.com/efficacy-and-safety-of-regorafenib-plus-immune-checkpoint-inhibitors-w-peer-reviewed-fulltext-article-JHC

Similar Items